Selection and preliminary application of a single stranded DNA aptamer targeting colorectal cancer serum. Issue 66 (27th November 2019)

• Record Type: Journal Article
• Authors: Li, Kun; Qi, Liqing; Gao, LiMing; Shi, Ming; Li, Jian; Liu, ZhiWei; Zhao, Lu
• Is Part Of: RSC advances. Volume 9:Issue 66(2019)
• Page Start: 38867
• Page End: 38876
• Publication Date: 2019-11-27
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c9ra04777h
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Aptamer Seq-2 with high affinity and selectivity was screened against colorectal cancer serum directly for clinical application. Abstract : Colorectal cancer is one of the common causes of malignant tumors in recent years, thus the discovery of potential compounds that detect the occurrence of colorectal cancer by efficient approaches is necessary. In this study, the method of systematic evolution of ligands by exponential enrichment (SELEX) was used for recognizing serum from colorectal cancer patients by a single-stranded DNA library of aptamers assisted by single-walled carbon nanotubes (SWCNTs) to remove single-stranded DNA with low affinity. Ten rounds of selection were applied using colorectal cancer serum as a target with the serum of healthy individuals as a control. As the result, we have successfully identified four candidate aptamers after high-throughput genome sequencing analysis, comparison analysis and secondary structure prediction. Among them, aptamer Seq-2 exhibited the highest affinity and the strongest selectivity with an equilibrium dissociation constant ( K d ) of 11.31 ± 3.25 nM and a C t difference value of 4.25 ± 0.38 between the colorectal cancer group and the healthy group. Moreover, with fifty negative control serum samples, the positive detection rate of fifty positive serum samples tested by aptamer Seq-2 was over 90%. In particular, aptamer Seq-2 can strongly bind the colorectal cancer serum, less strongly bind the non-colon cancer serum and hardly bind the healthy serum. Therefore, aptamer Seq-2 presents enormous potential for exploring as a tumor diagnostic kit and detecting unknown tumor markers in serum to reflect colorectal cancer.